Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition - PubMed (original) (raw)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
Shi-Yong Sun et al. Cancer Res. 2005.
Abstract
The mammalian target of rapamycin (mTOR) has emerged as an important cancer therapeutic target. Rapamycin and its derivatives that specifically inhibit mTOR are now being actively evaluated in clinical trials. Recently, the inhibition of mTOR has been shown to reverse Akt-dependent prostate intraepithelial neoplasia. However, many cancer cells are resistant to rapamycin and its derivatives. The mechanism of this resistance remains a subject of major therapeutic significance. Here we report that the inhibition of mTOR by rapamycin triggers the activation of two survival signaling pathways that may contribute to drug resistance. Treatment of human lung cancer cells with rapamycin suppressed the phosphorylation of p70S6 kinase and 4E-BP1, indicating an inhibition of mTOR signaling. Paradoxically, rapamycin also concurrently increased the phosphorylation of both Akt and eIF4E. The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process. The activated Akt and eIF4E seem to attenuate rapamycin's growth-inhibitory effects, serving as a negative feedback mechanism. In support of this model, rapamycin combined with LY294002 exhibited enhanced inhibitory effects on the growth and colony formation of cancer cells. Thus, our study provides a mechanistic basis for enhancing mTOR-targeted cancer therapy by combining an mTOR inhibitor with a PI3K or Akt inhibitor.
Similar articles
- Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun SY. Wang X, et al. Mol Cell Biol. 2007 Nov;27(21):7405-13. doi: 10.1128/MCB.00760-07. Epub 2007 Aug 27. Mol Cell Biol. 2007. PMID: 17724079 Free PMC article. - Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S. Takeuchi H, et al. Cancer Res. 2005 Apr 15;65(8):3336-46. doi: 10.1158/0008-5472.CAN-04-3640. Cancer Res. 2005. PMID: 15833867 - New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME, Shokat KM. Feldman ME, et al. Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review. - Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L. Martelli AM, et al. Curr Med Chem. 2007;14(19):2009-23. doi: 10.2174/092986707781368423. Curr Med Chem. 2007. PMID: 17691943 Review.
Cited by
- Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets.
Sehrawat U. Sehrawat U. Int J Mol Sci. 2024 Oct 9;25(19):10835. doi: 10.3390/ijms251910835. Int J Mol Sci. 2024. PMID: 39409166 Free PMC article. Review. - HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments.
Scheck MK, Hofheinz RD, Lorenzen S. Scheck MK, et al. Cancers (Basel). 2024 Mar 29;16(7):1336. doi: 10.3390/cancers16071336. Cancers (Basel). 2024. PMID: 38611014 Free PMC article. Review. - The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other Hemoglobinopathies.
Gambari R, Zuccato C, Cosenza LC, Zurlo M, Gasparello J, Finotti A, Gamberini MR, Prosdocimi M. Gambari R, et al. Biology (Basel). 2023 Sep 2;12(9):1202. doi: 10.3390/biology12091202. Biology (Basel). 2023. PMID: 37759601 Free PMC article. Review. - Exosomes are involved in the intercellular transfer of rapamycin resistance in the breast cancer cells.
Shchegolev YY, Sorokin DV, Scherbakov AM, Andreeva OE, Salnikova DI, Mikhaevich EI, Gudkova MV, Krasil'nikov MA. Shchegolev YY, et al. Bioimpacts. 2023;13(4):313-321. doi: 10.34172/bi.2023.27490. Epub 2023 Jul 1. Bioimpacts. 2023. PMID: 37645026 Free PMC article. - Biological functions and research progress of eIF4E.
Chen X, An Y, Tan M, Xie D, Liu L, Xu B. Chen X, et al. Front Oncol. 2023 Aug 3;13:1076855. doi: 10.3389/fonc.2023.1076855. eCollection 2023. Front Oncol. 2023. PMID: 37601696 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous